Mortara designs, develops and manufactures diagnostic cardiology and patient monitoring solutions. The company was founded in 1982 and today has more than 400 employees globally. In 2016, Mortara had approximately $115 million in revenue and a 55 percent gross margin.
Hill-Rom had almost $2.7 billion in revenue in fiscal 2016. The global medical technology company has 10,000 employees worldwide.
John Greisch, Hill-Rom president and chief executive officer, said Mortara would immediately strengthen the company’s Welch Allyn franchise.
“With Mortara, we will expand our diagnostic cardiology franchise in the acute care, clinical research and primary care settings, where we will use our global commercial presence to accelerate growth of the Mortara business,” Greisch said.
Mortara CEO Justin Mortara plans to join Hill-Rom and continue in a leadership capacity at the company. He will report to Hill-Rom Front Line president Alton Shader. The headquarters of Mortara is expected to stay in Milwaukee.
“By combining with Hill-Rom, Mortara Instrument will have greater opportunities to grow as part of a global leader with strong brand equity and unparalleled care setting expertise,” Mortara said. “Hill- Rom and Mortara Instrument share similar patient-centric cultures, and I am confident that this combination will benefit our valued employees and customers.”
Hill-Rom plans to structure the acquisition to qualify for a tax benefit of approximately $40 million, reducing the effective purchase price to around $290 million.
The deal will be financed with cash and existing credit facilities and is expected to close during the current quarter, the second of Hill-Rom’s fiscal year.
Hill-Rom projected the deal would benefit its adjusted earnings “modestly” in 2017 and said additional operational cost synergies of at least $10 million would result in more benefits in the future.